Refine by MP, party, committee, province, or result type.
Health committee I don't think it's as big an issue as it was years ago, because there's no pipeline and no new antibiotics that are making a profit for a pharmaceutical company. The investment in development of new antimicrobials has dropped.
November 2nd, 2017Committee meeting
Dr. Yoav Keynan
Health committee The drug solutions are also temporary and are never going to be able to keep up with the fundamentals of the components of the programs that we alluded to.
November 2nd, 2017Committee meeting
Dr. Yoav Keynan
Health committee That's a complex question. I don't know that I have an answer to it. Part of a healthy and balanced immune system is maintaining the normal microbiome, whatever the normal microbiome is, and exposure to antimicrobials has an effect on that. The disappearance of the natural protec
November 2nd, 2017Committee meeting
Dr. Yoav Keynan
Health committee With regard to addressing infections, no one in this room is saying that antibiotics should not be used. They should be used when appropriate. You start with the right antibiotics and you try to target. The problem becomes complicated in the presence of antimicrobial resistance.
November 2nd, 2017Committee meeting
Dr. Yoav Keynan
Health committee For me personally, and for the NCCID, the biggest revelation was the fact that public health physicians, the public officers of health of different jurisdictions, did not see antimicrobial stewardship or resistance as part.... They have millions of problems on their desks that ar
November 2nd, 2017Committee meeting
Dr. Yoav Keynan
Health committee Thank you, Chair and honourable members of the committee, for the opportunity to present here. My name is Yoav Keynan and I'm the scientific director of the National Collaborating Centre for Infectious Diseases, or NCCID. The six national collaborating centres for public health
November 2nd, 2017Committee meeting
Dr. Yoav Keynan